Maternal hair testing for the assessment of fetal exposure to drug of abuse during early pregnancy: Comparison with testing in placental and fetal remains

Forensic Science International

Volumn 218, Issue 1-3, 2012, Pages 92-96

  Falcon, M ^a   Pichini, S ^b   Joya, J ^c   Pujadas, M ^c   Sanchez, A ^a   Vall, O ^c,d   Algar, O García ^c,d   Luna, A ^a   de la Torre, R ^c   Rotolo, M C ^b   Pellegrini, M ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c HOSPITAL DEL MAR   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Drug abuse; Fetal and first trimester; Maternal hair; Placenta

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID; CANNABIS; COCAINE; DRUG METABOLITE; OPIATE;

ADOLESCENT; ADULT; ANALYTIC METHOD; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; ENVIRONMENTAL EXPOSURE; FEMALE; FIRST TRIMESTER PREGNANCY; GAS CHROMATOGRAPHY; GESTATION PERIOD; HAIR; HAIR ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MASS FRAGMENTOGRAPHY; OBSERVATIONAL STUDY; PLACENTA; PREGNANCY TERMINATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TOXICOKINETICS; VALIDATION PROCESS;

EID: 84860239227     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.10.022     Document Type: Article

References (37)

1. Huestis M.A., Choo R.E. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci. Int. 2002, 128(1):20-30.
2. Ostrea E.M., et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J. Pediatr. 2001, 138(8):344-348.
3. Pichini S., et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the Meconium Project. Forensic Sci. Int. 2005, 153(1):59-65.
4. Lozano J., et al. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther. Drug Monit. 2007, 29(6):711-734.
5. Llaquet H., et al. Biological matrices for the evaluation of exposure to environmental tobacco smoke during prenatal life and childhood. Anal. Bioanal. Chem. 2010, 396(1):379-399.
6. Society of Hair Testing, http://www.soht.org/.
7. Klein J., Karaskov T., Koren G. Clinical applications of hair testing for drugs of abuse-the Canadian experience. Forensic Sci. Int. 2000, 107(1-3):281-288.
8. Musshoff F., et al. Results of hair analyses for drugs of abuse and comparison with self-reports and urine tests. Forensic Sci. Int. 2006, 156(2-3):118-123.
9. Garcia-Bournissen F., et al. Cocaine detection in maternal and neonatal hair: implications to fetal toxicology. Ther. Drug Monit. 2007, 29(1):71-76.
10. Sastry B.V.R. Placental toxicology: tobacco smoke abused drugs, multiple chemical interactions and placental function. Reprod. Fertil. 1991, 3:355-372.
11. Han J.Y., Nava-Ocampo A.A., Koren G. Unintended pregnancies and exposure to potential human teratogens. Birth Defects Res. A: Clin. Mol. Teratol. 2005, 73:245-248.
12. Vähäkangas K., Myllynen P. Drug transporters in the human blood-placental barrier. Br. J. Pharmacol. 2009, 158(3):665-678.
13. Myllynen P., et al. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and embryonic tissues. Expert Opin. Drug Metab. Toxicol. 2009, 5(12):1483-1499.
14. Nanovskaya T., et al. Transplacental transfer and metabolism of buprenorphine. J. Pharmacol. Exp. Ther. 2002, 300(1):26-33.
15. Syme M.R., Paxton J.W., Keelan J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 2004, 43(8):487-514.
16. Aleksunes L.M., Cui Y., Klaassen C.D. Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. Drug Metab. Dispos. 2008, 36(9):1960-1970.
17. Pujadas M., et al. Development and validation of a gas chromatography-mass spectrometry assay for hair analysis of amphetamine, methamphetamine and methylenedioxy derivatives. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 798:249-255.
18. Jurado C., et al. Simultaneous quantification of opiates, cocaine and cannabinoids in hair. Forensic Sci. Int. 1995, 70:165-174.
19. Joya X., et al. Gas chromatography-mass spectrometry assay for the simultaneous quantification of drugs of abuse in human placenta at 12th week of gestation. Forensic Sci. Int. 2010, 196(1-3):38-42.
20. Barr D.B., Bishop A., Needham L.L. Concentrations of xenobiotic chemicals in the maternal-fetal unit. Reprod. Toxicol. 2007, 23(3):260-266.
21. Concheiro M., et al. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther. Drug Monit. 2010, 32(2):206-215.
22. de Castro A., et al. Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 2009, 33(5):243-252.
23. Wang P., et al. In utero drugs of abuse exposure testing for newborn twins. J. Clin. Pathol. 2010, 63:259-261.
24. Ebrahim S.H., Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet. Gynecol. 2003, 101:374-379.
25. Dott M., Rasmussen S.A., Hogue C.J., Reefhuis J. National Birth Defects Prevention Study, Association between pregnancy intention and reproductive-health related behaviors before and after pregnancy recognition, national birth defects prevention study 1997-2002. Matern. Child Health J. 2009.
26. Than L.C., Honein M.A., Watkins M.L., Yoon P.W., Daniel K.L., Correa A. Intent to become pregnant as a predictor of exposures during pregnancy: is there a relation?. J. Reprod. Med. 2005, 50:389-396.
27. Potter S., et al. Maternal cocaine use without evidence of fetal exposure. J. Pediatr. 1994, 125(4):652-654.
28. Huestis M.A. Human cannabinoid pharmacokinetics. Chem. Biodivers. 2007, 4(8):1770-1804.
29. Bailey J.R., et al. Toxicol. Appl. Pharmacol. 1987, 90:315.
30. Blackard C., Tennes K. Human placental transfer of cannabinoids. N. Engl. J. Med. 1984, 311:797.
31. Collier A.C., et al. Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum. Reprod. 2002, 17(10):2564-2572.
32. Rada B., et al. The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: a twin study. Can. J. Physiol. Pharmacol. 2001, 79(11):942-945.
33. Jurado C., et al. Hair testing for cannabis in Spain and France: is there a difference in consumption?. J. Anal. Toxicol. 1996, 20(2):111-115.
34. Tsanaclis L., John F.C. Wicks Patterns in drug use in the United Kingdom as revealed through analysis of hair in a large population sample. Forensic Sci. Int. 2007, 170:121-128.
35. Katikaneni L.D., Salle F.R., Hulsey T.C. Neonatal hair analysis for benzoylecgonine: a sensitive and semiquantitative biological marker for chronic gestational cocaine exposure. Biol. Neonat. 2002, 81(1):29-37.
36. Simone C., et al. Acetylcholinesterase and butyrylcholinesterase activity in the human term placenta: implications for fetal cocaine exposure. J. Lab. Clin. Med. 1994, 123(3):400-406.
37. Garcia-Bournissen F., et al. Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. Forensic Sci. Int. 2009, 189:24-27.